Cargando…
Frontiers in Clinical Drug Research - Hematology.
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Sharjah :
Bentham Science Publishers,
2018.
|
| Colección: | Frontiers in Clinical Drug Research - Hematology Ser.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro; CONTENTS; PREFACE; List of Contributors; Advances in the Understanding and Treatment of Immune Thrombocytopenia; José Perdomo*; INTRODUCTION; Platelet Biogenesis; Platelet Function; Epidemiology, Aetiology and Disease Progression; Platelet Destruction in ITP; Recent Developments; Impairment of Platelet Production in ITP; Disease Characteristics and Therapies; Need for Novel Therapies; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Recent Developments in Chronic Myeloid Leukemia Biology and Treatment.
- Massimiliano Bonifacio1,* and Claudio Sorio2,*INTRODUCTION; PART I: BIOLOGY; Signaling Mechanisms Altered in CML; Oncosuppressors Genes in CML: A Role for Cytosolic and Receptor-like PTPs; Oncogenic PTPs; Non-coding RNAs in CML; Other Tumor Promoting Pathways; Identifying Cancer Stem Cell in CML; Targeting LSCs; PART II: CLINICS; OPTIONS OF FRONT-LINE MANAGEMENT OF CML; Imatinib; Nilotinib; Dasatinib; Bosutinib and Ponatinib; THE SEQUENTIAL USE OF TKI IN SECOND OR FURTHER LINES OF TREATMENT; BCR-ABL Mutations; After Imatinib Failure; After Failure of Nilotinib or Dasatinib.
- Indications for HSCTTHE PROGNOSTIC SIGNIFICANCE OF EARLY MOLECULAR RESPONSE; Imatinib; Nilotinib; Dasatinib; Bosutinib; Absolute vs Relative Reduction of BCR-ABL1 Levels; Therapeutic Strategies Based on EMR; DEEP MOLECULAR RESPONSE AND DISCONTINUATION OF TREATMENT; Discontinuation Studies; Predictive Factors of DMR; The Impact of DMR on Survival; PREDICTING RESPONSE TO TKI; Risk Score Systems; Age; Comorbidities; Gender; Cytogenetic at Diagnosis; Transcript Type; Mutations; Predicting Response to 2G TKI After Imatinib Failure; New and Alternative Biomarkers of Response to Treatment.
- CONCLUDING REMARKSABBREVIATIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Role of Immunomodulatory Drugs in the Treatment of Lymphoid and Myeloid Malignancies; Ota Fuchs*; INTRODUCTION; CRL4CRBN as a Part of Ubiquitin-Proteasome System; Regulation of CRBN-Associated Proteins in Multiple Myeloma by Lenalidomide; Biomarker of Response or Resistance to Lenalidomide and Pomalidomide; Therapy for Multiple Myeloma Patients with Low CRBN Expression; Importance of CRBN for Immunomodulatory Drugs Activity in Lymphoid Malignancies.
- CLINICAL STUDIES IN LYMPHOID MALIGNANCIESRelapsed/ Refractory CLL; B-Cell NHL; Multiple Myeloma; CLINICAL STUDIES IN MYELOID MALIGNANCIES; Myelodysplastic Syndrome; Randomized Phase III Placebo-Controlled Study of Lenalidomide in del(5q) Patients; Further Clinical Studies of Lower Risk MDS Patients with del(5q) Treated with Lenalidomide; Treatment of del(5q) Patients with Relapse during Lenalidomide Exposure; Therapy with Lenalidomide in Combination with Another Drug in MDS; Mechanisms of Action of Lenalidomide.